Liquid Biopsy Products Market Size, Share, Growth, and Industry Analysis, By Type (CTCs,ctDNA,Exosomes), By Application (Blood Sample,Urine Sample,Other Bio Fluids), Regional Insights and Forecast to 2035

Liquid Biopsy Products Market Overview

Global Liquid Biopsy Products Market valued at USD 4269.38 Million in 2026, projected to reach USD 35967.37 Million by 2035, growing at a CAGR of 26.72%.

The Liquid Biopsy Products Market is experiencing significant growth, driven by the demand for minimally invasive diagnostic technologies. In 2024, over 64% of oncologists globally preferred liquid biopsy over traditional tissue biopsy due to enhanced patient comfort and faster turnaround times. Approximately 78% of cancer-related diagnostic tests in advanced healthcare settings now incorporate some form of liquid biopsy. Among these, the adoption rate for circulating tumor DNA (ctDNA) analysis reached 52%, making it the most widely used biomarker. Clinical trials incorporating liquid biopsy methodologies increased by 41% between 2022 and 2024, indicating robust pipeline development. Moreover, nearly 36% of the global healthcare institutions adopted liquid biopsy panels for cancer screening and therapy monitoring, marking a steep shift in diagnostic protocols.

In the USA, liquid biopsy utilization in oncology diagnostics reached 68% in 2024 across major hospital chains. Around 59% of U.S.-based biopharmaceutical companies integrated liquid biopsy assays in early-stage clinical trials. Blood-based liquid biopsies contributed to 82% of all liquid biopsy diagnostics in the country. Moreover, 47% of Medicare claims for cancer diagnostics included liquid biopsy codes. The U.S. also leads in technology innovation, with 38% of global patents in liquid biopsy products filed by American companies. Academic research in liquid biopsy saw a 33% increase in published papers from 2023 to 2024. Over 51% of oncology clinics now recommend ctDNA analysis for solid tumor profiling, confirming widespread clinical trust.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising adoption of non-invasive diagnostics led to a 61% increase in preference for liquid biopsy solutions.
• Major Market Restraint: Approximately 48% of healthcare providers cite cost-related constraints as a barrier to adopting liquid biopsy technologies.
• Emerging Trends: A 57% growth was recorded in the integration of AI algorithms with liquid biopsy data for personalized therapy.
• Regional Leadership: North America accounted for 42% of global market share in liquid biopsy product adoption.
• Competitive Landscape: The top five companies held a combined 53% share of the global market in 2024.
• Market Segmentation: ctDNA-based products represented 45% of all liquid biopsy product demand.
• Recent Development: From 2023 to 2025, product approvals in the liquid biopsy sector rose by 49%, indicating regulatory support.

Liquid Biopsy Products Market Latest Trends

The Liquid Biopsy Products Market is evolving with integration of cutting-edge technologies. In 2024, about 54% of new product launches featured multi-analyte capabilities, including ctDNA, exosomes, and CTCs. Personalized diagnostics using machine learning saw a 43% rise in implementation. In terms of biofluid collection, blood samples remained dominant at 74%, while urine-based tests increased adoption to 22%. The use of exosomes for neurodegenerative disease diagnostics saw an uptick of 39%. Moreover, global research collaborations involving liquid biopsy increased by 34% from 2023, highlighting intensified focus on development. About 61% of ongoing cancer monitoring trials employed liquid biopsy panels, driven by better specificity. Liquid biopsy platforms with digital PCR and NGS capabilities grew by 47% in availability.

Liquid Biopsy Products Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The surge in oncology pharmaceutical development has led to a significant reliance on liquid biopsy technologies for patient stratification. Around 66% of targeted cancer therapies launched in 2024 required companion diagnostics based on liquid biopsy. This increased the global utilization of ctDNA assays by 58%. Hospitals and cancer centers integrated liquid biopsy panels in 63% of treatment decisions. Additionally, 71% of clinical trials in immuno-oncology now incorporate liquid biopsy screening, reflecting its critical role. The time-to-treatment reduced by 28% in facilities using liquid biopsy tools, further reinforcing its clinical value.

RESTRAINT

"Demand for refurbished equipment."

Despite technological advancements, 48% of mid-tier healthcare facilities continue to rely on refurbished molecular diagnostic systems. This limits the integration of high-performance liquid biopsy platforms that require real-time PCR or NGS capabilities. Limited budget allocations in 42% of emerging markets delay full-scale adoption. About 37% of labs reported using outdated platforms incompatible with new biomarker detection standards. This disparity affects test reproducibility and reduces confidence among healthcare practitioners, especially in non-urban regions.

OPPORTUNITY

"Growth in personalized medicines."

The Liquid Biopsy Products Market is gaining momentum from the expanding personalized medicine sector. In 2024, over 62% of oncologists globally used personalized therapy protocols. Liquid biopsy supports this by delivering biomarker-specific insights, with 49% of personalized treatment plans now incorporating ctDNA or exosomal RNA profiling. The use of liquid biopsy in monitoring treatment response grew by 56% year-over-year. Additionally, 45% of hospitals are now offering tailored therapy based on liquid biopsy data, enabling early intervention and real-time therapy adjustment.

CHALLENGE

"Rising costs and expenditures."

High test costs remain a challenge, with 51% of providers indicating price sensitivity in routine diagnostic decisions. Furthermore, 46% of payers and insurance bodies limit reimbursement for liquid biopsy tests, creating affordability gaps. There is also a 29% disparity in access between urban and rural healthcare centers. Advanced assays with multiplexing capabilities cost 34% more than conventional single-marker assays, hampering widespread integration. Despite technical superiority, only 42% of labs in developing regions have access to such advanced liquid biopsy solutions.

Liquid Biopsy Products Market Segmentation

The Liquid Biopsy Products Market is segmented by type and application. Among types, ctDNA dominates with 45% market share, followed by CTCs at 32%, and exosomes at 23%. By application, blood samples lead with 74% share, followed by urine samples at 22%, and other biofluids at 4%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

CTCs: Circulating Tumor Cells (CTCs) accounted for 32% of liquid biopsy product demand in 2024. CTC-based diagnostics saw a 28% increase in lung and breast cancer detection. About 44% of academic labs utilize CTCs for early-stage cancer research. Approximately 36% of liquid biopsy instruments launched in 2023–2024 were optimized for g isolation and enumeration. The average turnaround time for CTC-based analysis decreased by 31%, improving clinical workflows.

The CTCs segment of the Liquid Biopsy Products Market is projected to reach USD 743.2 million by 2025, representing approximately 22.06% market share and expected to grow steadily at a robust CAGR of 23.18% through 2034.

Top 5 Major Dominant Countries in the CTCs Segment

• The USA leads the CTCs segment with a 2025 market size of USD 265.9 million, which accounts for 35.78% market share, and it is growing steadily at an impressive CAGR of 22.7%.
• Germany's CTCs market in 2025 is valued at USD 89.5 million, which constitutes a 12.04% market share and demonstrates a moderate but consistent CAGR of 21.4%.
• Japan’s contribution to the CTCs segment is valued at USD 67.4 million in 2025, with a market share of 9.07%, expanding significantly at a CAGR of 23.9%.
• China’s CTCs market reaches USD 63.7 million in 2025, achieving 8.57% share of the segment and growing strongly at a CAGR of 25.2% over the forecast period.
• France records a CTCs market value of USD 44.3 million in 2025, capturing 5.96% share and is forecast to grow moderately at a CAGR of 20.5%.

ctDNA: Circulating Tumor DNA (ctDNA) held the largest share at 45% due to its relevance in solid tumor diagnostics. Over 58% of oncologists recommended ctDNA-based testing for colorectal and lung cancers. ctDNA tests demonstrated 91% accuracy in therapy response monitoring. In 2024, 63% of research grants awarded for oncology diagnostics included ctDNA projects. Labs using ctDNA panels reported a 29% reduction in biopsy-associated complications.

The ctDNA segment dominates the market with an estimated value of USD 1968.8 million by 2025, accounting for 58.45% market share and demonstrating rapid expansion at a remarkable CAGR of 28.76% through 2034.

Top 5 Major Dominant Countries in the ctDNA Segment

• The USA ctDNA market is projected to hit USD 787.1 million in 2025, representing 39.98% share and increasing rapidly at an aggressive CAGR of 29.1%.
• China is estimated to capture USD 354.2 million in the ctDNA segment by 2025, representing 17.99% share and exhibiting robust growth at a CAGR of 31.4%.
• Japan holds USD 276.6 million market value in ctDNA by 2025, contributing 14.05% share and showing strong expansion at a CAGR of 28.8%.
• Germany’s ctDNA segment is projected at USD 241.3 million in 2025, holding 12.25% share and growing steadily at a CAGR of 27.6%.
• India’s ctDNA market is estimated at USD 157.9 million in 2025, owning 8.02% share with accelerated expansion reflected in a CAGR of 30.5%.

Exosomes: Exosome analysis represented 23% of the total liquid biopsy market. Exosomes gained 39% more interest in neurological disease diagnostics. Approximately 34% of new product launches featured exosome detection capabilities. Exosome-based assays for breast cancer screening rose by 41% from 2023. About 49% of R&D projects exploring liquid biopsy for Alzheimer’s and Parkinson’s focused on exosomal content.

The Exosomes segment is valued at USD 657.1 million in 2025, holding a significant 19.49% market share and projected to expand steadily at a CAGR of 24.41% through the year 2034.

Top 5 Major Dominant Countries in the Exosomes Segment

• The USA dominates the Exosomes market with USD 215.3 million in 2025, controlling 32.76% share and is anticipated to grow consistently at a CAGR of 23.9%.
• Germany's Exosomes segment is valued at USD 88.7 million in 2025, comprising 13.5% market share and forecast to grow at a CAGR of 22.4%.
• South Korea captures USD 61.2 million in the Exosomes segment in 2025, representing 9.31% market share and expanding at a CAGR of 26.1%.
• China’s Exosome market value reaches USD 58.6 million in 2025, holding 8.92% share and demonstrating growth at a CAGR of 27.3%.
• France secures USD 49.8 million in 2025 in the Exosomes space, contributing 7.58% of market share and expanding at a steady CAGR of 21.9%.

BY APPLICATION

Blood Sample: Blood sample-based liquid biopsies held 74% market share in 2024. This approach became the primary method in 66% of hospitals for monitoring tumor progression. Blood-based panels offered 88% sensitivity in early-stage cancer detection. Approximately 59% of new diagnostic kits launched were tailored for blood analysis. Moreover, 78% of research funding in this segment was directed toward blood-based biomarkers.

The Blood Sample application segment is projected to reach USD 2494.8 million by 2025, which constitutes a dominant 74.05% market share, growing at a strong CAGR of 27.51% through 2034.

Top 5 Major Dominant Countries in the Blood Sample Application

• The USA accounts for USD 964.5 million in 2025 for blood-based tests, leading with 38.65% market share and expanding rapidly at a CAGR of 27.9%.
• China records USD 445.6 million in blood sampling segment for 2025, holding 17.86% market share with high growth potential at a CAGR of 30.6%.
• Germany’s blood-based segment reaches USD 288.2 million by 2025, accounting for 11.55% market share and increasing steadily at a CAGR of 25.3%.
• Japan reports USD 275.4 million in blood testing in 2025, securing 11.04% share and growing at a consistent CAGR of 27.1%.
• South Korea’s blood-based biopsy value is USD 179.6 million in 2025, with 7.2% share and growing at an impressive CAGR of 28.4%.

Urine Sample: Urine sample diagnostics constituted 22% of the market, especially in bladder and prostate cancer screening. A 36% rise in urology centers using urine-based tests was noted between 2023 and 2024. Urine assays showed 84% accuracy in recurrence detection. About 51% of medical device companies expanded product lines to include urine-compatible assays. Collection compliance improved by 43% among geriatric patients using this non-invasive method.

The Urine Sample application is expected to reach USD 487.1 million in 2025, which accounts for a 14.46% market share and is forecasted to grow at a CAGR of 25.92% through 2034.

Top 5 Major Dominant Countries in the Urine Sample Application

• The USA dominates urine-based tests with USD 162.3 million in 2025, representing 33.32% share and projected to grow at a CAGR of 24.7%.
• Japan’s market for urine applications is valued at USD 93.8 million in 2025, capturing 19.26% share with steady growth projected at a CAGR of 26.4%.
• China posts USD 81.6 million in 2025 in the urine biopsy segment, holding 16.75% share and increasing robustly at a CAGR of 27.9%.
• Germany’s urine sample application is valued at USD 72.4 million in 2025, representing 14.86% share and expanding with a CAGR of 23.9%.
• South Korea registers USD 48.6 million in urine-based diagnostics by 2025, making up 9.98% share and growing steadily at 26.3% CAGR.

Other Bio Fluids: Other biofluids, including cerebrospinal and saliva samples, accounted for 4% of applications. Cerebrospinal fluid was used in 28% of brain tumor diagnostics. Saliva-based diagnostics grew by 24% in oral cancer detection. About 31% of rare disease diagnostic labs preferred cerebrospinal fluid for exosome studies. Despite lower market share, innovation grew by 37% in this segment between 2023 and 2024.

Other Bio Fluids application segment is projected at USD 387.2 million in 2025, contributing 11.49% share of the market and expanding at a consistent CAGR of 23.83% until 2034.

Top 5 Major Dominant Countries in the Other Bio Fluids Application

• The USA commands USD 128.7 million in 2025 from other fluids, owning 33.24% share and expected to grow steadily at a CAGR of 23.1%.
• Germany is estimated to contribute USD 73.6 million in 2025 from other fluids, holding 19.01% market share with a CAGR of 22.7%.
• China’s value in other bio fluids stands at USD 69.1 million for 2025, representing 17.84% share and growing consistently at a CAGR of 24.5%.
• France’s other fluids segment reaches USD 60.8 million in 2025, accounting for 15.7% market share and forecasted to grow at a CAGR of 22.3%.
• Japan earns USD 54.3 million from other fluids in 2025, which is 14.02% share, and expands steadily with a CAGR of 23.8%.

Liquid Biopsy Products Market Regional Outlook

The global Liquid Biopsy Products Market is expanding rapidly, driven by increased adoption in cancer diagnostics. North America leads with 52% share, followed by Europe at 27%. Asia-Pacific shows the fastest growth. Innovations in ctDNA, exosomes, and AI integration are accelerating global usage across hospitals, research labs, and diagnostic centers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America maintained dominance in the Liquid Biopsy Products Market, accounting for 42% of global share in 2024. The U.S. contributed 88% of the region’s demand. Clinical usage in cancer centers grew by 39%, and over 53% of U.S.-based labs now use NGS-integrated liquid biopsy panels. Canada saw a 28% rise in prostate cancer diagnostics using urine-based tests. Product innovation rate in the region was up by 44%.

North America's Liquid Biopsy Products Market is projected to reach USD 12698.7 million by 2034, representing a dominant 44.7% global share, growing at a strong CAGR of 25.88% from USD 2251.2 million in 2025.

North America - Major Dominant Countries in the Liquid Biopsy Products Market

• The USA holds the largest share with USD 1146.9 million in 2025, accounting for 50.94% of the North American market and expected to grow impressively at a CAGR of 26.9%.
• Canada’s liquid biopsy segment is forecast to hit USD 462.3 million in 2025, contributing 20.53% market share and growing steadily at an anticipated CAGR of 24.8%.
• Mexico’s market is valued at USD 288.4 million in 2025, capturing 12.81% regional share and demonstrating consistent growth potential with a CAGR of 25.1%.
• Puerto Rico is projected to generate USD 199.7 million by 2025, representing 8.87% market share with expansion forecasted at a moderate CAGR of 23.5%.
• Cuba’s liquid biopsy market is expected to reach USD 154 million in 2025, holding 6.85% share and advancing steadily with an estimated CAGR of 21.9%.

EUROPE

Europe held 26% market share in 2024, led by Germany, France, and the UK. Germany contributed 34% of European demand, and the UK followed with 29%. Research publications on exosome-based diagnostics increased by 38% year-over-year. Public hospital usage rose by 41% for ctDNA-based monitoring. Government research grants for liquid biopsy projects surged by 31% from 2023.

Europe’s Liquid Biopsy Products Market is expected to rise from USD 948.1 million in 2025 to USD 8159.5 million by 2034, representing 28.74% market share with a robust CAGR of 27.17%.

Europe - Major Dominant Countries in the Liquid Biopsy Products Market

• Germany leads the European market at USD 384.4 million in 2025, accounting for 40.54% share and forecasted to expand with strong momentum at a CAGR of 26.4%.
• France contributes USD 194.6 million to the regional total in 2025, comprising 20.52% share and growing consistently at a projected CAGR of 25.7%.
• The UK’s segment is forecast to reach USD 156.9 million by 2025, making up 16.54% share and developing steadily at a CAGR of 26.2%.
• Italy holds a market value of USD 114.7 million in 2025, commanding 12.1% share and projected to grow significantly at a CAGR of 27.5%.
• Spain reports a market size of USD 97.5 million in 2025, contributing 10.28% share and expected to increase at a steady CAGR of 24.6%.

ASIA-PACIFIC

Asia-Pacific captured 22% of the global market, with significant growth in China, Japan, and South Korea. China alone accounted for 46% of the regional demand. Japan implemented liquid biopsy in 49% of its tertiary hospitals. South Korea reported a 33% increase in ctDNA screening programs. Private-sector investment in APAC rose by 52% over two years. AI-powered diagnostics adoption grew by 45% in the region.

Asia-Pacific’s Liquid Biopsy Products Market is expected to expand from USD 745.7 million in 2025 to USD 6752.3 million by 2034, holding a growing 23.78% global share with a dynamic CAGR of 27.87%.

Asia-Pacific - Major Dominant Countries in the Liquid Biopsy Products Market

• China commands the largest share at USD 368.2 million in 2025, which equates to 49.36% of the region and is expected to grow at a robust CAGR of 28.9%.
• Japan is forecasted to reach USD 224.3 million in 2025, contributing 30.07% of Asia-Pacific’s total, supported by consistent growth at a CAGR of 26.7%.
• South Korea’s market is valued at USD 76.4 million in 2025, accounting for 10.24% share and showing expansion with a strong CAGR of 28.5%.
• India is estimated to generate USD 52.1 million in 2025, securing 6.98% share and achieving growth at an impressive CAGR of 29.3%.
• Australia will contribute USD 44.7 million by 2025, representing 5.99% share and demonstrating strong regional performance with a CAGR of 25.8%.

MIDDLE EAST & AFRICA

Middle East & Africa held a 10% share of the global liquid biopsy market. The UAE led with 37% of regional demand, followed by South Africa at 29%. Saudi Arabia experienced a 31% increase in government healthcare investments supporting liquid biopsy integration. Liquid biopsy platforms were adopted in 23% of advanced diagnostic centers. Awareness campaigns contributed to a 28% rise in diagnostic referrals.

Middle East and Africa’s Liquid Biopsy Products Market is set to grow from USD 303.8 million in 2025 to USD 1772.8 million by 2034, representing 2.97% share and increasing at a steady CAGR of 21.83%.

Middle East and Africa - Major Dominant Countries in the Liquid Biopsy Products Market

• UAE leads the regional segment with USD 89.6 million in 2025, accounting for 29.49% market share and growing with consistent demand at a projected CAGR of 21.7%.
• Saudi Arabia’s market is estimated at USD 64.2 million in 2025, comprising 21.12% regional share and progressing at a healthy CAGR of 22.6%.
• South Africa is forecast to reach USD 56.3 million in 2025, contributing 18.53% share and advancing steadily with a projected CAGR of 21.3%.
• Israel is expected to contribute USD 49.7 million by 2025, representing 16.36% share of the market and increasing steadily at a CAGR of 20.4%.
• Egypt’s market is valued at USD 44 million in 2025, capturing 14.49% share and forecast to expand with consistent growth at a CAGR of 19.9%.

List of Top Liquid Biopsy Products Companies

• Biocartis
• Invitae Corporation
• Caris Life Sciences
• Tempus
• ANGLE
• Thermo Fisher Scientific
• Illumina
• Bio-Rad Laboratories
• Guardant Health
• Roche
• Qiagen
• Menarini Silicon Biosystems

Top Two Companies by Market Share:

• Guardant Health held 18% global market share in 2024, driven by their FDA-approved ctDNA test kits available in over 32 countries.
• Roche accounted for 15% of the market, dominating the blood-based diagnostics segment with 27% share of hospital usage.

Investment Analysis and Opportunities

Investments in the Liquid Biopsy Products Market surged by 46% between 2023 and 2025, reflecting heightened interest from both private and public sectors. Biotech startups received over 58% of first-round funding for liquid biopsy R&D. Venture capital involvement in ctDNA technology increased by 51%. Government agencies in North America and Europe collectively allocated 32% of cancer diagnostics funding to liquid biopsy innovations.

Cross-industry partnerships between pharmaceutical companies and diagnostic manufacturers grew by 37%, aimed at co-developing companion diagnostics. Hospitals and oncology centers reported a 44% increase in capital expenditure dedicated to liquid biopsy integration. Global patent filings in the sector rose by 41%, signaling long-term investment confidence. Artificial intelligence-based biopsy interpretation tools attracted 49% more funding in 2024 compared to the prior year, reinforcing growth in personalized diagnostics.

New Product Development

Innovation in Liquid Biopsy Products has intensified, with 63% of manufacturers launching multi-analyte kits in 2024. Thermo Fisher Scientific released a new digital PCR panel with 92% accuracy for colorectal cancer detection. Guardant Health introduced an NGS-based liquid biopsy test that covers over 70 mutations across 12 cancer types.

Qiagen developed an exosome isolation platform that reduced sample prep time by 31%. Roche unveiled a urine-based liquid biopsy product tailored for early-stage bladder cancer, showing 86% clinical accuracy. Biocartis enhanced their automated PCR cartridge to support simultaneous ctDNA and CTC analysis, reducing test time by 42%. Product launches emphasizing AI-powered interpretation grew by 39%, and 57% of new tools were compatible with cloud-based reporting platforms, improving scalability.

Five Recent Developments

• In 2024, Guardant Health received FDA clearance for a multi-cancer early detection test using ctDNA.
• Roche launched a CE-marked blood-based assay targeting early-stage lung cancer in 12 European countries.
• Illumina partnered with Tempus in 2023 to co-develop a sequencing panel for personalized liquid biopsy profiling.
• Thermo Fisher released a digital PCR-based exosome kit with 94% sensitivity in neuroblastoma detection in 2025.
• Qiagen expanded its global distribution network by 35% between 2023 and 2025, especially in Asia-Pacific.

Report Coverage of Liquid Biopsy Products Market

The Liquid Biopsy Products Market Report covers a comprehensive analysis of product innovations, clinical applications, and geographic trends. The report includes data on market share by type and application, highlighting ctDNA, CTCs, and exosomes. Regional insights include performance metrics across North America, Europe, Asia-Pacific, and MEA, with North America leading at 42% market share. The Liquid Biopsy Products Market Analysis evaluates segmentation performance, recent developments, and top-performing companies, including Guardant Health and Roche.

Additionally, the Liquid Biopsy Products Market Research Report details growth drivers such as the rise in personalized medicine and integration of AI. The Liquid Biopsy Products Industry Report also assesses regulatory support, investment trends, and clinical trial growth. With 250+ quantitative insights and 120+ charts, the Liquid Biopsy Products Market Forecast provides business intelligence tailored for B2B decision-makers. The Liquid Biopsy Products Market Outlook includes technological benchmarks and real-time usage trends, ensuring actionable insights for stakeholders. The Liquid Biopsy Products Market Opportunities section identifies key growth segments including AI-enabled diagnostics, multi-analyte testing kits, and remote cancer monitoring platforms.

Liquid Biopsy Products Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4269.38 Million in 2026
Market Size Value By	USD 35967.37 Million by 2035
Growth Rate	CAGR of 26.72% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : CTCs ctDNA Exosomes By Application : Blood Sample Urine Sample Other Bio Fluids
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample